View Older Stories View More Recent Stories
-
Regeneron to present EYLEA HD data at Angiogenesis meeting
-
Regeneron Pharma (REGN) PT Raised to $800 at Wells Fargo
-
Regeneron Pharma (REGN) PT Raised to $742 at Baird
-
Regeneron (REGN) Tops Q4 EPS by 92c
-
Regeneron Pharma (REGN) PT Raised to $916 at Bernstein
-
RBC Capital Reiterates Sector Perform Rating on Regeneron Pharma (REGN)
-
BofA Securities on Regeneron Pharma (REGN): 'Updating model for 4Q Eylea and other recent disclosures'
-
Regeneron Pharma (REGN) PT Raised to $875 at Evercore ISI
-
Regeneron Pharma (REGN) PT Raised to $820 at Raymond James
-
Stifel: 'REGN Announcements Validate APGE Thesis'
-
4Q25/2026 Biotech Earnings Preview: RBC
-
Goldman: 'Top Call Buying Opportunities for 2026'
-
BofA double-upgrades Regeneron, citing stronger Eylea outlook and 2026 catalysts
-
BofA Securities Double Upgrades Regeneron Pharma (REGN) to Buy
-
BTIG on Apogee (APGE): 'DUPLEX-AD's Failure is Likely a Clearing Event for APG279 and APG777 in Atopic Dermatitis'
-
Japan approves Dupixent for children with severe asthma
-
Trump to announce prescription drug price agreements
-
Regeneron Pharma (REGN) PT Raised to $873 at Leerink Partners
-
RBC Capital on Regeneron Pharma (REGN): 'We Continue to Seek a Better Entry Point'
-
Regeneron reports trial results for Lynozyfic in newly diagnosed myeloma
-
Regeneron Pharma (REGN) PT Raised to $850 at BMO Capital
-
Regeneron Pharma (REGN) PT Raised to $1,057 at Canaccord Genuity
-
Morgan Stanley Downgrades Regeneron Pharma (REGN) to Equalweight
-
Bernstein Weighs In on Regeneron Pharma (REGN) Following Tessera Deal
-
Regeneron and Tessera partner on gene editing therapy for rare disease
-
Dupixent wins EU approval for chronic spontaneous urticaria treatment
-
Truist Securities Assumes Regeneron Pharma (REGN) at Buy
-
HSBC Starts Regeneron Pharma (REGN) at Buy
-
Regeneron Pharma (REGN) Shares Are Almost Back to Positive - Cantor Fitzgerald
-
Bernstein on Regeneron Pharma (REGN): 'Positive Surprise'
-
Regeneron Pharma (REGN) PT Raised to $700 at Wells Fargo
-
Regeneron Pharma (REGN) PT Raised to $800 at Raymond James
-
After-hours movers: NVIDIA, CoreWeave, Palo Alto Networks, and more
-
FDA approves EYLEA HD for retinal vein occlusion treatment
-
Regeneron (REGN) Halted, News Pending
-
Regeneron gets EU approval for LIBTAYO as adjuvant CSCC treatment
-
Regeneron presents blood cancer data at ASH hematology conference
-
Regeneron Pharma (REGN) PT Raised to $725 at BMO Capital
-
Regeneron Pharma (REGN) PT Raised to $740 at Cantor Fitzgerald
-
OPKO's ModeX partners with Regeneron on multispecific antibodies
-
Regeneron Pharma (REGN) PT Raised to $865 at Guggenheim
-
Regeneron Pharma (REGN) PT Raised to $627 at BofA Securities
-
Regeneron Pharma (REGN) PT Raised to $630 at Baird
-
Regeneron Pharma (REGN) PT Raised to $700 at Citi
-
Regeneron (REGN) Tops Q3 EPS by 219c
-
Bernstein's US Biotech 3Q25 Preview: 'Expect Beats from ALNY and REGN'
-
European drug panel recommends Regeneron's Libtayo for skin cancer use
-
Regeneron presents new cancer treatment data at ESMO meeting
-
Canaccord Genuity Reiterates Buy Rating on Regeneron Pharma (REGN)
-
Scholar Rock stock falls after FDA flags issues at manufacturing facility

